Lung Cancer

The FDA accepted a new drug application for zidesamtinib for previously treated locally advanced or metastatic ROS1-positive non-small cell lung cancer.

The FDA has approved Hyrnuo for some with locally advanced or metastatic non-squamous non–small cell lung cancer with activating mutations.

The FDA approved Imdelltra after a study showed longer survival compared with chemotherapy in advanced small cell lung cancer.

Dr. Benjamin Herzberg spotlighted some of the “weird and wacky” new ideas in the field of targeted therapies for the treatment of lung cancer.

Dr. Adam J. Schoenfeld delivered an extensive overview of how cellular therapies are shaping the future of lung cancer care.

Dr. Catherine A. Shu highlights targeted therapies for patients with lung cancer, emphasizing advances, challenges and the importance of clinical trials.

LiveLung invites the Tampa area lung cancer community to its monthly educational meeting.

LiveLun invites the Fort Myers lung cancer community to its monthly educational meeting.

Dave Nitsche, a nonsmoker and endurance athlete, pushes back against stigma and stays active while advocating for lung cancer screening.

October brought updates in the lung cancer field, ranging from notable trial results to patient perspectives on navigating treatment and survivorship.

More than a quarter of tested patients with non-small cell lung cancer responded to Amtagvi monotherapy.

LiveLung invites the CSRA’s lung cancer community to its educational meeting.

LiveLung invites the Charlotte lung cancer community to its monthly educational meeting.

LiveLung invites the community to its monthly Small Cell Lung Cancer (SCLC) virtual educational meeting.

A cancer survivor explains how humor helped her during her cancer journey.

In October 2025, the FDA granted approval to multiple new cancer therapies and supportive care options, covering treatments across the oncologic landscape.

LiveLung invites the Wilmington community to its monthly educational meeting.

My first oncologist got me started with positivity in my cancer journey, which I was thankfully able to internalize.

Alecensa cut the risk of death by 22% versus Xalkori, with median overall survival reaching 81.1 months versus 54.2 months in advanced ALK-positive lung cancer.

The Beamion LUNG-1 study showed that first-line Hernexeos had benefit for patients with HER2-mutated NSCLC.

Alecensa achieved a 98.4% 4-year overall survival rate versus 92.4% with chemotherapy in resected ALK-positive early-stage lung cancer.

Ivonescimab plus chemotherapy significantly improved progression-free survival versus Tevimbra advanced squamous non–small cell lung cancer.

Sacituzumab tirumotecan cut risk of progression or death by 51% versus chemotherapy in EGFR-mutated NSCLC after tyrosine kinase inhibitor resistance.

Consolidation tiragolumab plus Tecentriq does not improve progression-free survival in advanced lung cancer compared to Imfinzi.

Clinical trial data support the use of Imdelltra as a standard of care for all patients with second-line small cell lung cancer.